SCHEMBL7499745

SCHEMBL7499745

CCc1cc(C)cc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.37
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
NR3C2 P08235 1/20 0.36
LMNA P02545 1/20 0.35
IDO1 P14902 2/20 0.34
RAPGEF4 Q8WZA2 3/20 0.34
PTGS2 P35354 2/20 0.33
PGK1 P00558 1/20 0.32
PGK2 P07205 1/20 0.32
NOS3 P29474 3/20 0.31
NOS2 P35228 2/20 0.31
NOS1 P29475 2/20 0.31
IDH1 O75874 1/20 0.31
RPS6KB1 P23443 1/20 0.31
TP53 P04637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ALOX5 P09917 1/20 0.31
PTGS1 P23219 1/20 0.31
HDAC3 O15379 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148110 0.84 IDO1 (0.46) NR3C1PGRNR3C2LMNAIDO1
SCHEMBL12658317 0.84 LMNA (0.41) LMNAIDO1PTGS2TP53L3MBTL1
SCHEMBL14570491 0.82 ACHE (0.39) ACHENR3C1PGRNR3C2IDO1
SCHEMBL16958903 0.81 FFAR4 (0.39) ACHENR3C1PGRNR3C2IDO1
SCHEMBL168174 0.81 PGK1 (0.44) RAPGEF4PTGS2PGK1PGK2NOS3
SCHEMBL271754 0.81 ALDH1A1 (0.42) ACHENR3C1PGRNR3C2RAPGEF4
SCHEMBL5490825 0.81 PGK1 (0.44) RAPGEF4PTGS2PGK1PGK2NOS3
SCHEMBL2662788 0.80 ACHE (0.37) ACHENR3C1PGRNR3C2IDO1
Ammonia Solution, Strong SCHEMBL5606944 0.78 PGK1 (0.42) RAPGEF4PTGS2PGK1PGK2NOS3
SCHEMBL257934 0.78 ACHE (0.36) ACHENR3C1PGRNR3C2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364082-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-11-16 US disclosed
EP-3609868-B1 TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS RAQUALIA PHARMA INC (JP) 2023-10-18 EP disclosed
US-11752149-B2 Muscarinic acetylcholine M1 receptor antagonists Pipeline Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 US disclosed
US-20230145050-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NodThera Limited (GB) 2023-05-11 US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-20220402929-A1 PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF TOCOPHERX INC (US) 2022-12-22 US disclosed
EP-4106070-A1 PHOSPHORUS-CONTAINING ELECTROLYTES Nohms Technologies, Inc. (US) 2022-12-21 EP disclosed
US-11518757-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2022-12-06 US disclosed
EP-1939204-B3 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2022-08-24 EP disclosed
WO-2007145922-A2 BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2007-12-21 WO disclosed
EP-1847533-A1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF Asahi Kasei Pharma Corporation (JP) 2007-10-24 EP disclosed
EP-1345943-B1 INHIBITORS OF PAPILLOMA VIRUS BOEHRINGER INGELHEIM CA LTD (CA) 2007-03-21 EP disclosed
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use IPSEN PHARMA S.A.S. (FR) 2007-02-22 US disclosed
CN-1100056-C Compound for inhibition of gastric acid secretion ASTRA AB (SE) 2003-01-29 CN disclosed
EP-0971920-B1 COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION ASTRAZENECA AB (SE) 2002-06-05 EP disclosed
US-6265415-B1 ANTIULCER AGENT ASTRAZENECA AB (SE) 2001-07-24 US disclosed
CN-1248257-A Compound for inhibition of gastric acid secretion ASTRA AB (SE) 2000-03-22 CN disclosed
EP-0971920-A1 COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION Astra Aktiebolag (SE) 2000-01-19 EP disclosed
WO-1998037080-A1 COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION ASTRA AKTIEBOLAG (SE) 1998-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364082-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM5 ACHE 22/4885NR3C1 349/4885PGR 1298/4885
US-20230145050-A1 SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS NLRP3, NOD1, IL1B ACHE 4770/4885NR3C1 3875/4885PGR 4760/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ACHE 4750/4885NR3C1 382/4885PGR 1596/4885
US-20220402929-A1 PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF FSHR, GNRHR, LHCGR ACHE 3510/4885NR3C1 176/4885PGR 15/4885
US-11752149-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM5 ACHE 22/4885NR3C1 349/4885PGR 1298/4885
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SSTR2, SSTR5, SSTR3 ACHE 3427/4885NR3C1 273/4885PGR 335/4885
US-11661397-B2 1,4-disubstituted imidazole derivative NR4A3, NR0B1, NR2C2 ACHE 4550/4885NR3C1 8/4885PGR 356/4885
US-11518757-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NLRP3, NOD1, IL1B ACHE 4770/4885NR3C1 3875/4885PGR 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.